Global Lung Cancer Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Lung Cancer Type;

Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).

By Diagnostic Test;

Imaging Test, Sputum Cytology, Biopsy, Molecular Tests, and Others.

By End Use;

Hospitals and Clinics, Diagnostic Laboratories and, Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn148953161 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Lung Cancer Diagnostics Market (USD Million), 2021 - 2031

In the year 2024, the Global Lung Cancer Diagnostics Market was valued at USD 116,373.74 million. The size of this market is expected to increase to USD 200,610.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.1%.

Lung cancer remains one of the most prevalent and deadliest forms of cancer worldwide, prompting significant attention in diagnostics and treatment. The global lung cancer diagnostics market is witnessing remarkable growth, driven by several factors. Firstly, the increasing incidence of lung cancer, particularly among smokers and individuals exposed to environmental pollutants, underscores the urgent need for effective diagnostic solutions. Additionally, advancements in diagnostic technologies, such as imaging modalities like CT scans and MRI, as well as the emergence of molecular diagnostics and biomarker testing, have revolutionized the detection and management of lung cancer.

Rising awareness campaigns and government initiatives aimed at early detection and screening programs have further fueled market expansion. These efforts emphasize the importance of timely diagnosis in improving patient outcomes and reducing mortality rates associated with lung cancer. Furthermore, the growing adoption of minimally invasive procedures for biopsy and tissue sampling, coupled with the integration of artificial intelligence (AI) and machine learning algorithms in diagnostic platforms, are enhancing accuracy and efficiency in lung cancer detection.

The global lung cancer diagnostics market is characterized by intense competition and a diverse range of market players, including diagnostic laboratories, medical device manufacturers, and healthcare providers. Companies are increasingly focusing on research and development activities to introduce innovative diagnostic solutions, thereby augmenting their market presence. With the continuous evolution of diagnostic technologies and the increasing emphasis on personalized medicine, the lung cancer diagnostics market is poised for substantial growth in the foreseeable future.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Lung Cancer Type
    2. Market Snapshot, By Diagnostic Test
    3. Market Snapshot, By End Use
    4. Market Snapshot, By Region
  4. Global Lung Cancer Diagnostics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Advanced screening technologies
        2. Rising incidence of lung cancer
        3. Growing awareness and early detection
        4. Technological advancements in diagnostics
      2. Restraints
        1. High costs of diagnostic procedures
        2. Limited accessibility in rural areas
        3. Regulatory hurdles for new technologies
        4. Lack of skilled healthcare professionals
      3. Opportunities
        1. Emerging markets expansion
        2. Personalized medicine and targeted therapies
        3. Integration of AI in diagnostics
        4. Collaborative research and development efforts
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Lung Cancer Diagnostics Market, By Lung Cancer Type, 2021 - 2031 (USD Million)
      1. Small cell lung cancer (SCLC)
      2. Non-small cell lung cancer (NSCLC)
    2. Global Lung Cancer Diagnostics Market, By Diagnostic Test, 2021 - 2031 (USD Million)
      1. Imaging Test
      2. Sputum cytology
      3. Biopsy
      4. Molecular tests
      5. Others
    3. Global Lung Cancer Diagnostics Market, By End Use, 2021 - 2031 (USD Million)
      1. Hospitals and Clinics
      2. Diagnostic Laboratories
      3. Others
    4. Global Lung Cancer Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. F. Hoffmann-La Roche Ltd
      2. Thermo Fisher Scientific Inc
      3. Abbott Laboratories
      4. Siemens Healthineers AG
      5. Bio-Rad Laboratories, Inc
      6. Qiagen N.V
      7. Illumina, Inc
      8. Biocept, Inc
      9. Agilent Technologies, Inc
      10. Myriad Genetics, Inc
  7. Analyst Views
  8. Future Outlook of the Market